MAGEA2B
gene geneOn this page
Also known as MAGE2MGC16973MAGEA2
Summary
MAGEA2B (MAGE family member A2B, HGNC:19340) is a protein-coding gene on chromosome Xq28, encoding Melanoma-associated antigen 2 (P43356). Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites.
This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. This gene has two identical copies at different loci.
Source: NCBI Gene 266740 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 1 total
- MANE Select transcript:
NM_001386132
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:19340 |
| Approved symbol | MAGEA2B |
| Name | MAGE family member A2B |
| Location | Xq28 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | MAGE2, MGC16973, MAGEA2 |
| Ensembl gene | ENSG00000183305 |
| Ensembl biotype | protein_coding |
| OMIM | 300549 |
| Entrez | 266740 |
Gene structure
Transcript identifiers
Ensembl transcripts: 41 — 38 protein_coding, 3 protein_coding_CDS_not_defined
ENST00000331220, ENST00000370293, ENST00000409560, ENST00000422085, ENST00000423993, ENST00000447530, ENST00000453150, ENST00000458057, ENST00000467743, ENST00000492402, ENST00000497578, ENST00000682532, ENST00000921037, ENST00000921038, ENST00000921039, ENST00000921040, ENST00000921041, ENST00000921042, ENST00000921043, ENST00000921044, ENST00000921045, ENST00000921046, ENST00000921047, ENST00000921048, ENST00000921049, ENST00000921050, ENST00000921051, ENST00000921052, ENST00000921053, ENST00000921054, ENST00000921055, ENST00000921056, ENST00000921057, ENST00000921058, ENST00000921059, ENST00000921060, ENST00000921061, ENST00000921062, ENST00000921063, ENST00000921064, ENST00000921065
RefSeq mRNA: 7 — MANE Select: NM_001386132
NM_001321400, NM_001321401, NM_001321402, NM_001321403, NM_001321404, NM_001386132, NM_153488
CCDS: CCDS76046
Canonical transcript exons
ENST00000682532 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001595771 | 152717042 | 152718607 |
| ENSE00001613800 | 152716896 | 152716961 |
| ENSE00001664534 | 152715957 | 152716076 |
| ENSE00001717176 | 152715079 | 152715157 |
| ENSE00001800090 | 152714628 | 152714682 |
Expression profiles
Bgee: expression breadth broad, 58 present calls, max score 82.18.
Top tissues by expression
106 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 82.18 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 81.02 | silver quality |
| testis | UBERON:0000473 | 52.18 | gold quality |
| left testis | UBERON:0004533 | 51.34 | gold quality |
| right testis | UBERON:0004534 | 50.84 | gold quality |
| colonic epithelium | UBERON:0000397 | 42.35 | gold quality |
| granulocyte | CL:0000094 | 39.03 | gold quality |
| placenta | UBERON:0001987 | 38.70 | gold quality |
| bone marrow cell | CL:0002092 | 38.21 | gold quality |
| sural nerve | UBERON:0015488 | 37.80 | gold quality |
| ventricular zone | UBERON:0003053 | 36.48 | gold quality |
| cortical plate | UBERON:0005343 | 36.47 | gold quality |
| ganglionic eminence | UBERON:0004023 | 35.49 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 35.16 | gold quality |
| Ammon’s horn | UBERON:0001954 | 35.11 | gold quality |
| primary visual cortex | UBERON:0002436 | 34.88 | gold quality |
| substantia nigra | UBERON:0002038 | 34.09 | gold quality |
| prefrontal cortex | UBERON:0000451 | 33.39 | gold quality |
| bone marrow | UBERON:0002371 | 32.79 | gold quality |
| lymph node | UBERON:0000029 | 32.43 | gold quality |
| muscle tissue | UBERON:0002385 | 32.37 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 32.15 | gold quality |
| frontal cortex | UBERON:0001870 | 31.30 | gold quality |
| ectocervix | UBERON:0012249 | 31.22 | silver quality |
| right coronary artery | UBERON:0001625 | 31.08 | silver quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 30.88 | gold quality |
| putamen | UBERON:0001874 | 30.68 | silver quality |
| cerebral cortex | UBERON:0000956 | 30.29 | gold quality |
| Brodmann (1909) area 9 | UBERON:0013540 | 29.91 | gold quality |
| leukocyte | CL:0000738 | 29.89 | silver quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-CURD-53 | no | 38.12 |
| E-ANND-3 | no | 0.16 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
24 targeting MAGEA2B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-4789-3P | 99.99 | 70.75 | 2484 |
| HSA-MIR-4775 | 99.98 | 75.00 | 6394 |
| HSA-MIR-590-3P | 99.96 | 74.34 | 6478 |
| HSA-MIR-7162-3P | 99.89 | 68.16 | 1682 |
| HSA-MIR-383-3P | 99.85 | 65.84 | 1359 |
| HSA-MIR-202-3P | 99.84 | 71.41 | 1290 |
| HSA-MIR-6515-3P | 99.82 | 68.19 | 1933 |
| HSA-MIR-4694-3P | 99.79 | 69.53 | 2640 |
| HSA-MIR-466 | 99.67 | 70.85 | 2863 |
| HSA-MIR-4499 | 99.62 | 67.29 | 1470 |
| HSA-MIR-4261 | 99.59 | 70.30 | 3415 |
| HSA-MIR-147B-5P | 99.45 | 70.62 | 2432 |
| HSA-MIR-4427 | 99.34 | 70.33 | 1854 |
| HSA-MIR-324-3P | 99.26 | 66.31 | 1034 |
| HSA-MIR-892C-5P | 99.16 | 70.56 | 2116 |
| HSA-MIR-1227-5P | 98.65 | 65.32 | 1549 |
| HSA-MIR-31-5P | 98.58 | 68.35 | 1239 |
| HSA-MIR-6509-3P | 98.32 | 67.33 | 1343 |
| HSA-MIR-12120 | 98.05 | 68.44 | 1768 |
| HSA-MIR-96-3P | 97.47 | 68.03 | 839 |
| HSA-MIR-6750-3P | 96.79 | 67.50 | 740 |
| HSA-MIR-6857-3P | 96.70 | 65.43 | 915 |
| HSA-MIR-151A-3P | 95.52 | 65.29 | 516 |
| HSA-MIR-5195-5P | 90.84 | 65.09 | 287 |
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | ndnl2 | ENSDARG00000058212 |
| mus_musculus | Magea13 | ENSMUSG00000046180 |
| rattus_norvegicus | Magea13 | ENSRNOG00000003532 |
| drosophila_melanogaster | MAGE | FBGN0037481 |
Paralogs (37): MAGEC2 (ENSG00000046774), TRO (ENSG00000067445), MAGEB2 (ENSG00000099399), MAGED2 (ENSG00000102316), MAGEB4 (ENSG00000120289), MAGEA9 (ENSG00000123584), MAGEA10 (ENSG00000124260), MAGEA4 (ENSG00000147381), MAGED4 (ENSG00000154545), MAGEC1 (ENSG00000155495), MAGEA8 (ENSG00000156009), MAGEC3 (ENSG00000165509), MAGEB6 (ENSG00000176746), MAGEB18 (ENSG00000176774), MAGEF1 (ENSG00000177383), MAGEB10 (ENSG00000177689), MAGED1 (ENSG00000179222), NDN (ENSG00000182636), MAGEB17 (ENSG00000182798), NSMCE3 (ENSG00000185115), MAGEA11 (ENSG00000185247), MAGEE2 (ENSG00000186675), MAGED4B (ENSG00000187243), MAGEH1 (ENSG00000187601), MAGEB5 (ENSG00000188408), MAGEB16 (ENSG00000189023), MAGEA6 (ENSG00000197172), MAGEA1 (ENSG00000198681), MAGEB3 (ENSG00000198798), MAGEE1 (ENSG00000198934), MAGEA12 (ENSG00000213401), MAGEB1 (ENSG00000214107), MAGEA3 (ENSG00000221867), MAGEB6B (ENSG00000232030), MAGEL2 (ENSG00000254585), MAGEA9B (ENSG00000267978), MAGEA2 (ENSG00000268606)
Protein
Protein identifiers
Melanoma-associated antigen 2 — P43356 (reviewed: P43356)
Alternative names: Cancer/testis antigen 1.2, MAGE-2 antigen
All UniProt accessions (7): P43356, B9A060, E7ENJ0, E7EP80, E7EQY6, E7ER35, E9PC03
UniProt curated annotations — full annotation on UniProt →
Function. Reduces p53/TP53 transactivation function through recruitment of HDAC3 to p53/TP53 transcription sites. Also represses p73/TP73 activity. Proposed to enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. In vitro enhances ubiquitin ligase activity of TRIM28 and stimulates p53/TP53 ubiquitination by TRIM28 potentially in presence of Ubl-conjugating enzyme UBE2H. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes. Negatively regulates acetylation and sumoylation of PML and represses PML-induced p53/TP53 acetylation and activation.
Subunit / interactions. Interacts with TRIM28 and UBE2H. Interacts with HDAC3. Interacts with PML (isoform PML-1, isoform PML-2, isoform PML-3, isoform PML-4 and isoform PML-5).
Subcellular location. Nucleus. PML body.
Tissue specificity. Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes.
RefSeq proteins (7): NP_001308329, NP_001308330, NP_001308331, NP_001308332, NP_001308333, NP_001373061, NP_705692 (=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR002190 | MHD_dom | Domain |
| IPR021072 | MAGE_N | Domain |
| IPR037445 | MAGE | Family |
| IPR041898 | MAGE_WH1 | Homologous_superfamily |
| IPR041899 | MAGE_WH2 | Homologous_superfamily |
Pfam: PF01454, PF12440
UniProt features (7 total): compositionally biased region 2, chain 1, domain 1, region of interest 1, modified residue 1, mutagenesis site 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P43356-F1 | 71.63 | 0.43 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (1): 64
Mutagenesis-validated functional residues (1):
| Position | Phenotype |
|---|---|
| 170 | improves ability to bind to hla-a1. |
Function
Pathways and Gene Ontology
Reactome pathways
0 pathways
MSigDB gene sets: 69 (showing top):
BROWNE_HCMV_INFECTION_30MIN_DN, MODULE_52, GOBP_REGULATION_OF_PROTEIN_SUMOYLATION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, GOBP_CELLULAR_SENESCENCE, ACEVEDO_LIVER_CANCER_WITH_H3K27ME3_UP, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_PEPTIDYL_LYSINE_MODIFICATION, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION, GOBP_PROTEIN_ACETYLATION, GOBP_PROTEIN_SUMOYLATION, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_REGULATION_OF_PROTEIN_ACETYLATION, GOBP_NEGATIVE_REGULATION_OF_PROTEIN_METABOLIC_PROCESS
GO Biological Process (7): negative regulation of transcription by RNA polymerase II (GO:0000122), protein catabolic process (GO:0030163), negative regulation of protein sumoylation (GO:0033234), positive regulation of ubiquitin-protein transferase activity (GO:0051443), signal transduction by p53 class mediator (GO:0072331), cellular senescence (GO:0090398), negative regulation of protein acetylation (GO:1901984)
GO Molecular Function (4): ubiquitin protein ligase binding (GO:0031625), histone deacetylase binding (GO:0042826), DNA-binding transcription factor binding (GO:0140297), protein binding (GO:0005515)
GO Cellular Component (2): nucleus (GO:0005634), PML body (GO:0016605)
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| regulation of transcription by RNA polymerase II | 1 |
| transcription by RNA polymerase II | 1 |
| negative regulation of DNA-templated transcription | 1 |
| macromolecule catabolic process | 1 |
| protein metabolic process | 1 |
| protein sumoylation | 1 |
| regulation of protein sumoylation | 1 |
| negative regulation of protein modification by small protein conjugation or removal | 1 |
| ubiquitin-protein transferase activity | 1 |
| positive regulation of protein ubiquitination | 1 |
| positive regulation of catalytic activity | 1 |
| regulation of ubiquitin-protein transferase activity | 1 |
| intracellular signal transduction | 1 |
| cellular process | 1 |
| cellular response to stress | 1 |
| protein acetylation | 1 |
| negative regulation of protein modification process | 1 |
| regulation of protein acetylation | 1 |
| ubiquitin-like protein ligase binding | 1 |
| enzyme binding | 1 |
| transcription factor binding | 1 |
| binding | 1 |
| intracellular membrane-bounded organelle | 1 |
| nuclear body | 1 |
Protein interactions and networks
STRING
444 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| MAGEA2B | CTAG1A | P78358 | 812 |
| MAGEA2B | CTAG2 | O75638 | 787 |
| MAGEA2B | CSAG2 | Q9Y5P2 | 670 |
| MAGEA2B | GAGE4 | P0DSO3 | 662 |
| MAGEA2B | PMEL | P40967 | 605 |
| MAGEA2B | TRIM28 | Q13263 | 598 |
| MAGEA2B | TP53 | P04637 | 589 |
| MAGEA2B | CSAG1 | Q6PB30 | 542 |
| MAGEA2B | DDX43 | Q9NXZ2 | 538 |
| MAGEA2B | TYR | P14679 | 522 |
| MAGEA2B | GAGE2A | Q6NT46 | 507 |
| MAGEA2B | A0A1W2PQG5 | A0A1W2PQG5 | 506 |
| MAGEA2B | ESR1 | P03372 | 489 |
| MAGEA2B | XAGE1B | Q9HD64 | 473 |
| MAGEA2B | MAGEF1 | Q9HAY2 | 455 |
IntAct
111 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| TP53 | MAGEA2 | psi-mi:“MI:0915”(physical association) | 0.730 |
| MAGEA2 | TP53 | psi-mi:“MI:0915”(physical association) | 0.730 |
| TP53 | MAGEA2 | psi-mi:“MI:0407”(direct interaction) | 0.730 |
| SEPTIN5 | MAGEA2 | psi-mi:“MI:0915”(physical association) | 0.670 |
| MAGEA2 | P4HA3 | psi-mi:“MI:0915”(physical association) | 0.670 |
| TRIM28 | MAGEA2 | psi-mi:“MI:0915”(physical association) | 0.670 |
| MAGEA2 | TRIM28 | psi-mi:“MI:0403”(colocalization) | 0.670 |
| MAGEA2 | HDAC3 | psi-mi:“MI:0407”(direct interaction) | 0.590 |
| MAGEA2 | HDAC3 | psi-mi:“MI:0914”(association) | 0.590 |
| MAGEA2 | HDAC3 | psi-mi:“MI:0915”(physical association) | 0.590 |
| MAGEA2 | GCD7 | psi-mi:“MI:0915”(physical association) | 0.560 |
| TIM10 | MAGEA2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| CSN9 | MAGEA2 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MAGEA2 | TIM10 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MAGEA2 | CEP57 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MAGEA2 | SMARCD1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MAGEA2 | PSMC1 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MAGEA2 | ANKRD45 | psi-mi:“MI:0915”(physical association) | 0.560 |
| MAGEA2 | COQ4 | psi-mi:“MI:0915”(physical association) | 0.560 |
BioGRID (74): MAGEA2B (Two-hybrid), MAGEA2B (Two-hybrid), MAGEA2B (Two-hybrid), MAGEA2B (Two-hybrid), MAGEA2B (Two-hybrid), P4HA3 (Two-hybrid), CEP57L1 (Two-hybrid), ANKRD45 (Two-hybrid), MDM2 (Reconstituted Complex), MDM2 (Affinity Capture-Western), MAGEA2 (Affinity Capture-Western), MDM2 (Protein-peptide), MAGEA2 (Reconstituted Complex), MAGEA2B (Two-hybrid), CEP57 (Two-hybrid)
ESM2 similar proteins: A0A0J9YX57, A1A5P9, A2A368, A2A9R3, A8MXT2, B2KFW1, O15479, O15480, O15481, O15553, P0C6Y7, P10073, P17040, P25233, P43355, P43356, P43357, P43358, P43360, P43362, P43363, P43364, P43366, Q13342, Q16666, Q4R998, Q5PPP4, Q5RD14, Q6AY37, Q6PCZ4, Q8BQR7, Q8IWY8, Q8IX06, Q8N660, Q8N7X4, Q8TD90, Q96DU7, Q96LZ2, Q96M61, Q99608
Diamond homologs: A0A0J9YX57, A1A5P9, A2A368, A2A9R3, A6NCF6, A6QLI5, A8MXT2, O15479, O15480, O15481, O60732, P25233, P43355, P43356, P43357, P43358, P43360, P43361, P43362, P43363, P43364, P43365, P43366, Q12816, Q4R998, Q5PPP4, Q5RFC2, Q6AY37, Q6ITT4, Q6PCZ4, Q8BQR7, Q8N7X4, Q8TD90, Q8TD91, Q96JG8, Q96LZ2, Q96M61, Q96MG7, Q99608, Q9BE18
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
1 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 1 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1503 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| X:152714679:CAAGG:C | donor_loss | 1.0000 |
| X:152714681:AGGT:A | donor_loss | 1.0000 |
| X:152714683:G:C | donor_loss | 1.0000 |
| X:152714684:T:G | donor_loss | 1.0000 |
| X:152716957:GATCT:G | donor_gain | 1.0000 |
| X:152716962:G:GG | donor_gain | 1.0000 |
| X:152717039:CAG:C | acceptor_loss | 1.0000 |
| X:152717040:A:AG | acceptor_gain | 1.0000 |
| X:152717041:G:GG | acceptor_gain | 1.0000 |
| X:152717041:GGCCT:G | acceptor_gain | 1.0000 |
| X:152751424:CAGGC:C | acceptor_gain | 1.0000 |
| X:152751429:C:CA | acceptor_loss | 1.0000 |
| X:152751429:C:CC | acceptor_gain | 1.0000 |
| X:152751430:T:A | acceptor_loss | 1.0000 |
| X:152751507:A:AC | donor_gain | 1.0000 |
| X:152751508:C:CC | donor_gain | 1.0000 |
| X:152751508:CAGAT:C | donor_gain | 1.0000 |
| X:152753783:CTTA:C | donor_loss | 1.0000 |
| X:152753784:TTA:T | donor_loss | 1.0000 |
| X:152753785:TACC:T | donor_loss | 1.0000 |
| X:152753787:C:CA | donor_loss | 1.0000 |
| X:152716959:TCT:T | donor_gain | 0.9900 |
| X:152716959:TCTG:T | donor_loss | 0.9900 |
| X:152716960:CTGTA:C | donor_loss | 0.9900 |
| X:152716961:TG:T | donor_loss | 0.9900 |
| X:152716962:GTA:G | donor_loss | 0.9900 |
| X:152716963:T:TC | donor_loss | 0.9900 |
| X:152716964:A:AG | donor_loss | 0.9900 |
| X:152716965:AGTA:A | donor_loss | 0.9900 |
| X:152716966:G:GG | donor_gain | 0.9900 |
AlphaMissense
0 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1158210873 (X:152712825 G>A), RS1171897735 (X:152719042 A>G), RS1191818001 (X:152712897 A>G), RS1200776749 (X:152713000 C>T), RS1216799183 (X:152713125 C>T), RS1218097441 (X:152713266 C>T), RS1247186365 (X:152712956 G>A), RS1262788224 (X:152749566 C>A), RS1275907309 (X:152713276 AG>A), RS1277635313 (X:152713257 T>TG), RS1284883702 (X:152713100 A>G), RS1297963481 (X:152713336 A>G), RS1312103317 (X:152712669 G>A), RS1324664565 (X:152712764 C>T), RS1331009015 (X:152712759 A>G)
Disease associations
OMIM: gene MIM:300549 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
7 total (human), top 7 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| butyraldehyde | increases expression | 1 |
| Decitabine | increases expression | 1 |
| Valproic Acid | increases methylation | 1 |
| Aflatoxin B1 | increases methylation | 1 |
| Cadmium Chloride | decreases expression | 1 |
| Okadaic Acid | increases expression | 1 |
| S-Nitrosoglutathione | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.